Table 2.

Clinical–pathological features of all melanoma patients enrolled in the study by sex

Features	Clinical–pathological features of 1023 melanoma patients
	Male patients (n = 487)	Female patients (n = 536)	Pa
TMN stage (2009 AJCC melanoma staging system)
Stage 0	72 (14.8%)	109 (20.3%)	0.025
Stage I	243 (49.9%)	306 (57.2%)	0.025
Stage II	103 (21.1%)	80 (15%)	0.012
Stage III	23 (4.7%)	17 (3.2%)	0.264
Stage IV	14 (2.9%)	9 (1.7%)	0.281
Unknown/not applicable	32 (6.6%)	15 (2.8%)	–
Pathological TNM stage (pT)
pTis	72 (14.8%)	107 (20.0%)	0.036
pT1	188 (38.6%)	241 (45.0%)	0.046
pT2	78 (16.0%)	88 (16.4%)	0.929
pT3	64 (13.1%)	49 (9.1%)	0.053
pT4	50 (10.3%)	32 (6.0%)	0.016
Unknown/not applicable	35 (7.2%)	19 (3.6%)	–
Histological ulceration
Present	80 (16.4%)	52 (9.7%)	0.002
Absent	312 (64.1%)	363 (67.7%)	0.243
Unknown/not applicable	95 (19.5%)	121 (22.6%)	0.261
Tumor-infiltrating lymphocytes
Absent	297 (61.0%)	348 (64.9%)	0.215
Non-brisk	123 (25.3%)	134 (25.0%)	0.982
Brisk	37 (7.6%)	37 (6.9%)	0.758
Unknown/not applicable	30 (6.2%)	17 (3.2%)	–

Values in table are presented as the number (of patients) with the percentage in parenthesis

P ≤ 0.05 indicates a significant difference

^aHomogeneity of proportions were obtained using the Pearson chi-squared test with Yates’ continuity correction, where necessary